Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, ...

Please provide your email address to receive an email when new articles are posted on . Hepatocellular carcinoma accounts for approximately 90% of all primary liver cancer cases, according to Zhen-Wei ...

BOSTON - An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in ...

Please provide your email address to receive an email when new articles are posted on . Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for ...

A study was conducted to compare cardiovascular outcomes for single-pill antihypertensive combination therapy and identical multiple pill therapy. Risk for CV events and all-cause mortality is ...

A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field. Children with ...

HOUSTON - A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the ...

Bristol-Myers Squibb Company today announced five-year results from the Phase 3 CheckMate -067 clinical trial, which continues to demonstrate improved overall survival with the first-line combination ...

Researchers at the University of California, San Diego (UCSD) School of Medicine report that treating patients with personalized, combination therapies improved outcomes in patients with ...

49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society ...